Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

ROI in Pharmaceutical R&D: How to Halt the Decline - ResearchAndMarkets.com

January 3, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 3, 2020--

The “ROI in Pharmaceutical R&D: How to Halt the Decline” report has been added to ResearchAndMarkets.com’s offering.

This report investigates recent years of performance of pharmaceutical and biopharmaceutical companies with respect to return on investment (ROI) in research and development (R&D), and to discuss ways that companies are trying to improve ROI through 2024.

Many factors enter into the calculation of ROI; this is not a straightforward calculation, especially if one does not have access to the company’s internal accounting books. However, the fact that many factors enter into the calculation, also may be taken to mean that a number of factors might be adjusted or developed to improve ROI. Laying off employees is one way, but this is not effective longer-term unless the company is at the same time reorganizing for greater efficiency. Sanofi, for example, hit hard by pricing pressure in diabetes, started laying off 400 US sales employees in June 2019 but states that it is also undergoing a reorganization to its salesforce.

The most significant route to decreasing costs and improving failure rates is to cut off the development of a failing drug as early as possible in order to focus on potential winners. Pretty obvious - but how best to do this?

Many pharma and biotech companies are exploring the use of technology to make the most of clinical development and clinical trials. In the next three to five years:

The scope of this study begins with the challenges facing biotech and pharmaceutical companies today. It goes on to discuss regulatory approval processes in various countries, how these are changing, and the knock-on effects which the pharma/biotech companies will have to address. The report then reviews several key financial ratios, then discusses how to maximize clinical development success rate. We then go into how machine learning (ML) and artificial intelligence (AI), along with Big Data, are disrupting the pharma/biotech industry, in a positive way. The report then reviews the global markets for treatments for selected cancers, chronic diseases, cardiovascular disease, neurological diseases, infectious diseases and rare diseases. Chapter 15 discusses how companies need to deeply integrate ML, AI and Big Data into drug discovery and clinical testing - or risk falling behind the competition. The report wraps up with summaries of selected companies active in these spaces and beginning to utilize digital tools in R&D.

The Report Includes:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/rk0shx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com:https://www.businesswire.com/news/home/20200103005227/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/03/2020 09:33 AM/DISC: 01/03/2020 09:33 AM